CEO/President, Dr. Michael Men M.D: He is also the CEO and Chairman of Alum Developing LLC, CEO and Chairman of Enrich Solar. As a co-founder and Angel investor, Dr. Men has extensive experience in company management, financing, international collaborations.

 

CTO/Vice President, Dr. Xiaofang Wang M.D., Ph.D.: Former senior postdoctoral fellow of University of Connecticut. Dr. Wang worked for the first stem cell company in China (Sinocells Biotechnology Co LTD) as the CIO and Manager of the Clinical Research Department for two years before he came to USA. He earned his Ph.D. degree in immunology at the MD. Anderson Cancer Center, and then worked at Yale University School of Medicine for two years. He joined Dr. Ren-He Xu’s stem cell core lab at University of Connecticut Health Center in 2008. He has extensive expertise in immunology and stem cell biology, and is a key inventor of the technologies mentioned in this proposal. He also has experience in operation of stem cell-based biotechnology companies, clinical trials, and financing.

 

 

Scientific Advisory Board:

 

Hongkui Deng Ph.D.: Dr. Hongkui Deng is a Professor of Cell Biology and Genetics, College of Life Sciences, Peking University. Mr. Deng had served as Member of Scientific Advisory Board at Stemgent, Inc. He is best known for the development of small chemical induced pluripotent stem cell and development of stem cells that can produce natural. He is one of the winners of the Bill & Melinda Gates Foundation's Grand Challenges in Global Health. He won $1.9 million for a proposal to use stem cells to create mouse models for testing HIV and hepatitis C vaccines. Mr. Deng received his Ph.D. in Immunology at the University of California at Los Angeles.

 

Lingheng Li Ph.D.: Investigator of Stowers Institute of Medical Research, founded by Mr. Stowers, President of USA Epoch Common Fund, with US $ 2 Billion investment. Co-leader, Cancer Biology, The University of Kansas Cancer Center. Professor of Pathology and Laboratory Medicine, The University of Kansas School of Medicine. Dr. Li is a renowned stem cell scientist focusing on cancer stem cell, hematopoietic stem cell and intestinal stem cells, with plenty of publications in top journals like Cell, Nature, Science and Cell Stem Cell etc.

 

Joel S. Pachter Ph.D.: Professor of Department of Cell Biology University of Connecticut Health Center. Dr. Pachter is an expert in the neuroinflammatory and neurodegenerative diseases fields such as multiple sclerosis. His lab is specialized in using Laser capture microdissection based technology to study he blood brain barrier (BBB) of central nerve system (CNS). Dr. Pachter is also a collaborator of ImStem on company's CT stem cell grant focusing on using hES-MSC to treat multiple sclerosis.

 

David Hafler M.D., MSc: Gilbert H. Glaser Professor of Neurology and Professor of Immunobiology; Chair, Department of Neurology, Yale School of Medicine. Dr. Hafler is renowned physician and scientist on neurology, immunology, especially in the field of multiple sclerosis. Dr. Hafler's laboratory has been a major force in defining human autoimmune disease for over a quarter of a century. After demonstrating the presence of an activated peripheral immune system in patients with MS, he was among the first to apply human T cell cloning to human disease. He was among the first to describe regulatory T cells, and Th17 cells in humans. He continues to be active as a clinician, and has led a number of clinical trials, including the first therapy of human autoimmune disease with monoclonal antibodies in the 1980s. After a sabbatical with Eric Lander at the Broad Institute, Hafler led the first whole genome scan identifying gene variants associated with MS. Dr. Hafler is Founder and past president of the Federation of Clinical Immunology Societies and is an NIH Jacob Javits Scholar.

 

Collaborators:

 

Martin Grumet Ph.D. : Professor, Cell Biology & Neuroscience, Keck Center for Collaborative Neuroscience, Rutgers University. Focusing on using neural stem cell and mesenchymal stem cell to treat spinal cord injury, Dr. Grumet has developed a capsulation system to increase the function and survival of mesenchymal stem cell in spinal cord injury treatment. Dr. Grumet is collaborating with ImStem on spinal cord injury treatment.

 

David Rowe M.D.: Professor and Director of Center for Regenerative Medicine and Skeletal Development, Department of Reconstructive Sciences School of Dental Medicine, University of Connecticut Health Center. Dr. David Rowe has been named the recipient of the 2010 UConn Health Center Board of Directors Faculty Recognition Award. His main research interest is the human genetic disease Osteogenesis imperfecta, commonly known as Brittle Bone Disease. He is also one of the lead researchers in UConn's new Stem Cell Institute. He heads nine discrete projects at the Health Center, with grants totaling $3.5 million: Directing hES Derived Progenitor Cells into Musculoskeletal Lineages. Collectively, the participating researchers are studying how embryonic stem cells could help rebuild bone, cartilage, skin, and muscle. Now he is collaborating with ImStem on bone repair and skin repair.